Liquidia amends HealthCare Royalty financing to add up to $100 million
Liquidia Technologies, a wholly owned subsidiary of Liquidia Corporation, signed a Sixth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV on March 17, 2025, adding up to $100 million in financing in three tranches. The company received $25.0 million at the effective date, with the remaining tranches tied to YUTREPIA commercial milestones. Repayments are capped at 175% of amounts advanced and follow a fixed schedule ending in 2032, so the added funding comes with a defined repayment obligation.
Key points
- $25.0 million funded on the March 17, 2025 effective date
- $50.0 million to be funded after the first commercial sale of YUTREPIA following final FDA approval for PAH and PH-ILD, absent an injunction
- $25.0 million to be funded by mutual agreement if aggregate YUTREPIA net sales exceed $100 million on or before June 30, 2026
- Aggregate payments capped at 175% of amounts advanced; fixed payment schedule terminates in 2032
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 18, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.